CytoDyn Inc. (OTCMKTS: CYDY) announced superb top-line data in their mild to moderate COVID-19 phase 2 trial and did not disappoint; however,...
CytoDyn Inc. (OTCMKTS: CYDY) announced groundbreaking safety results from its phase 2 Mild to Moderate COVID-19 trial today. The company reported a...
Gilead Sciences Inc. (NASDAQ:GILD) on Nov 11, said its new Harvoni drug for hepatitis C achieved cure rates of 96 percent to...
Petroleo Brasileiro Petrobras SA (ADR) (NYSE:PBR) announces that its consolidated oil and gas production, in Brazil and abroad, reached 2 million 795...
Gilead Sciences (NASDAQ:GILD)‘s stock had its “positive” rating reaffirmed by research analysts at Robert W. Baird in a report released on Monday....
Johnson & Johnson (JNJ) won U.S. approval for its hepatitis C drug Olysio to be used in combination with Gilead Sciences Inc....
Itau Unibanco Holding SA (ADR) (NYSE:ITUB), Brazil’s second-largest bank by assets, on Tuesday reported a 35% increase in third-quarter profit and said...
Gilead Sciences Inc. (NASDAQ:GILD) on Oct. 28 reported third-quarter profit of $2.73 billion. On a per-share basis, the company said it had...
Equities research analysts at Edward Jones started coverage on shares of Gilead Sciences (NASDAQ:GILD) in a research note issued to investors on...
Gilead Sciences Inc. (NASDAQ:GILD)’s EVP Paul Rutherford Carter sold 2,000 shares of Gilead Sciences stock on the open market in a transaction...